Press Releases

 
Press Releases
  Date Title View
Apr 17, 2017
CAMBRIDGE, Mass., April 17, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that Daryl Drummond, Ph.D. has been appointed Head of Research. Dr. Drummond, an expert and pioneer in the field of nanotherapeutics, has held various leadership roles at Merrimack, including most recently as Vice President of Discovery a...
Apr 5, 2017
CAMBRIDGE, Mass., April 5, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that its Board of Directors has authorized and declared a special cash dividend of $140 million on the company's common stock. This special dividend will be paid from the proceeds of the company's asset sale to Ipsen S.A., which was comple...
Apr 3, 2017
CAMBRIDGE, Mass., April 3, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that it has commenced operating as a new, refocused research and clinical development company in connection with the completion today of its previously announced transaction with Ipsen S.A. valued at up to $1.025 billion. Under the terms o...
Mar 30, 2017
CAMBRIDGE, Mass., March 30, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) ("Merrimack") announced that, at its Special Meeting of Stockholders held today, its stockholders voted to approve the asset sale with Ipsen S.A. under which Merrimack will: Sell to Ipsen its first commercial product ONIVYDE®, including U...
Mar 27, 2017
CAMBRIDGE, Mass., March 27, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present preclinical and clinical data from its oncology pipeline at the 2017 American Association for Cancer Research (AACR) Annual Meeting, April 1-5, 2017 at the Walter E. Washington Convention Center, Washington, D.C.. Of ...
Mar 23, 2017
CAMBRIDGE, Mass., March 23, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the enrollment of its first patient in a Phase 1 study of MM-310 in solid tumors. MM-310 is an antibody-directed nanotherapeutic (ADN) that encapsulates a novel taxane and targets the EphA2 receptor, a protein which surveys suggest is ove...
Mar 1, 2017
CAMBRIDGE, Mass., March 1, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced its fourth quarter and full year 2016 financial results for the period ended December 31, 2016. Key Recent Events As announced on January 8, 2017, Merrimack entered into an asset purchase and sale agreement with Ipsen S....
Feb 22, 2017
CAMBRIDGE, Mass., Feb. 22, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its Fourth Quarter 2016 investor conference call and webcast at 8:30 a.m., Eastern time, on Wednesday, March 1.    The call will cover an update on Merrimack's r...
Jan 18, 2017
CAMBRIDGE, Mass., Jan. 18, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) ("Merrimack" or the "Company") today announced that Richard Peters, M.D., Ph.D., has been appointed as the Company's President and Chief Executive Officer, effective February 6, 2017, at which time he will also be appointed to the Merrimack Board of Direc...
Jan 8, 2017
CAMBRIDGE, Mass., Jan. 8, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) ("Merrimack" or the "Company") today announced that it has entered into a definitive asset purchase and sale agreement with Ipsen (Euronext: IPN; ADR: IPSEY) for a transaction valued at up to $1.025 billion, plus up to $33 million in net milestone payments...
FirstPrevious
2
...
NextLast
= add release to Briefcase

In this section, you will find several of Merrimack’s high-resolution images. All images here are copyrighted by Merrimack Pharmaceuticals, Inc., and are made available here for editorial use only. By downloading and/or using any of the Merrimack’s images, you acknowledge the rights of Merrimack’s images, and you agree to comply with the usage guidelines.

X

Accept | Decline